Quarterly Results Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Net Sales
1,381.66
419.48
377.83
407.64
337.08
302.52
274.10
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
1,381.66
419.48
377.83
407.64
337.08
302.52
274.10
Raw Material Cost
99.89
80.42
71.57
66.02
70.59
68.28
64.75
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
13.62
15.84
14.78
14.45
14.32
10.97
5.72
Selling and Distribution Expenses
261.93
199.24
178.63
161.55
199.38
165.89
114.12
Other Expenses
26.70
21.00
22.46
18.59
18.03
17.83
23.68
Total Expenditure (Excl Depreciation)
642.50
505.47
489.58
427.89
464.58
423.40
421.42
Operating Profit (PBDIT) excl Other Income
739.2
-86
-111.7
-20.2
-127.5
-120.9
-147.3
Other Income
74.10
70.71
77.93
57.08
-30.86
126.01
32.47
Operating Profit (PBDIT)
837.47
11.72
-6.13
60.70
-133.26
30.92
-90.93
Interest
13.62
15.84
14.78
14.45
14.32
10.97
5.72
Exceptional Items
-2.15
0.17
2.57
2.74
-1.12
-6.71
-7.32
Gross Profit (PBDT)
1,281.76
339.06
306.26
341.62
266.49
234.23
209.35
Depreciation
32.56
32.43
31.83
31.54
30.07
30.25
27.81
Profit Before Tax
789.14
-36.38
-50.17
17.44
-178.77
-17.02
-131.77
Tax
4.15
2.97
3.38
2.05
0.25
-0.00
0.03
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
775.39
-37.51
-51.85
19.21
-178.68
-14.77
-128.93
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
775.39
-37.51
-51.85
19.21
-178.68
-14.77
-128.93
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
10.15
-2.17
-2.22
-3.73
-2.50
-4.13
-3.08
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
785.54
-39.68
-54.07
15.48
-181.18
-18.90
-132.01
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
8,606.24
7,284.98
7,343.50
7,240.93
7,157.15
7,527.24
7,426.69
Earnings per share (EPS)
0.44
-0.02
-0.03
0.01
-0.1
-0.01
-0.07
Diluted Earnings per share
0.44
-0.02
-0.03
0.01
-0.1
-0.01
-0.07
Operating Profit Margin (Excl OI)
52.89%
-21.79%
-30.67%
-6.85%
-39.3%
-41.43%
-55.16%
Gross Profit Margin
59.47%
-0.94%
-4.85%
12.02%
-44.11%
4.38%
-37.93%
PAT Margin
56.12%
-8.94%
-13.72%
4.71%
-53.01%
-4.88%
-47.04%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Dec 2025 is 309.88% vs 55.06% in Dec 2024
Consolidate Net Profit
YoY Growth in quarter ended Dec 2025 is 533.50% vs -57.70% in Dec 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Dec 2025 is 845.51% vs 43.46% in Dec 2024
Interest
YoY Growth in quarter ended Dec 2025 is -4.90% vs 180.39% in Dec 2024
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Dec 2025 has improved from Dec 2024
Compare Quarterly Results Of InnoCare Pharma Ltd. With
Figures in Million
Consolidate Quarterly Results
Change(HKD)
Change(%)
Net Sales
1,381.66
0
1,381.66
Other Operating Income
0.00
0.00
0.00
Total Operating income
1,381.66
0
1,381.66
Raw Material Cost
99.89
0
99.89
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
13.62
0
13.62
Selling and Distribution Expenses
261.93
0
261.93
Other Expenses
26.70
0.00
26.70
Total Expenditure (Excl Depreciation)
642.50
0
642.50
Operating Profit (PBDIT) excl Other Income
739.16
0.00
739.16
Other Income
74.10
0
74.10
Operating Profit (PBDIT)
837.47
0
837.47
Interest
13.62
0
13.62
Exceptional Items
-2.15
0
-2.15
Gross Profit (PBDT)
1,281.76
0
1,281.76
Depreciation
32.56
0
32.56
Profit Before Tax
789.14
0
789.14
Tax
4.15
0
4.15
Provisions and contingencies
0
0
0.00
Profit After Tax
775.39
0
775.39
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
775.39
0
775.39
Share in Profit of Associates
0
0
0.00
Minority Interest
10.15
0
10.15
Other related items
0.00
0.00
0.00
Consolidated Net Profit
785.54
0
785.54
Equity Capital
0
0
0.00
Face Value
0.00
0
0.00
Reserves
8,606.24
0
8,606.24
Earnings per share (EPS)
0.44
0
0.44
Diluted Earnings per share
0.44
0
0.44
Operating Profit Margin (Excl OI)
52.89%
0%
0.00
52.89%
Gross Profit Margin
59.47%
0%
0.00
59.47%
PAT Margin
56.12%
0%
0.00
56.12%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 138.17 Million
in Dec 2025Figures in Million
QoQ Growth in quarter ended Dec 2025 is 229.37% vs 11.04% in Sep 2025
YoY Growth in quarter ended Dec 2025 is 309.88% vs 55.06% in Dec 2024
Quarterly - Consolidate Net Profit
Consolidate Net Profit 78.55 Million
in Dec 2025Figures in Million
QoQ Growth in quarter ended Dec 2025 is 2,078.59% vs 26.62% in Sep 2025
YoY Growth in quarter ended Dec 2025 is 533.50% vs -57.70% in Dec 2024
Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 76.34 Million
in Dec 2025Figures in Million
QoQ Growth in quarter ended Dec 2025 is 1,393.90% vs 29.85% in Sep 2025
YoY Growth in quarter ended Dec 2025 is 845.51% vs 43.46% in Dec 2024
Quarterly - Interest
Interest 1.36 Million
in Dec 2025Figures in Million
QoQ Growth in quarter ended Dec 2025 is -13.92% vs 6.76% in Sep 2025
YoY Growth in quarter ended Dec 2025 is -4.90% vs 180.39% in Dec 2024
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 52.89%
in Dec 2025Figures in %
QoQ Growth in quarter ended Dec 2025 has improved from Sep 2025
YoY Growth in quarter ended Dec 2025 has improved from Dec 2024
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
